150 related articles for article (PubMed ID: 15729708)
1. Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
Lu SX; Takach EJ; Solomon M; Zhu Q; Law SJ; Hsieh FY
J Pharm Sci; 2005 Apr; 94(4):788-97. PubMed ID: 15729708
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
Vallabhajosula S; Smith-Jones PM; Navarro V; Goldsmith SJ; Bander NH
Prostate; 2004 Feb; 58(2):145-55. PubMed ID: 14716739
[TBL] [Abstract][Full Text] [Related]
3. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
Lewis MR; Raubitschek A; Shively JE
Bioconjug Chem; 1994; 5(6):565-76. PubMed ID: 7873659
[TBL] [Abstract][Full Text] [Related]
4. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions.
Lewis MR; Shively JE
Bioconjug Chem; 1998; 9(1):72-86. PubMed ID: 9460549
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
[TBL] [Abstract][Full Text] [Related]
6. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
Kukis DL; DeNardo SJ; DeNardo GL; O'Donnell RT; Meares CF
J Nucl Med; 1998 Dec; 39(12):2105-10. PubMed ID: 9867151
[TBL] [Abstract][Full Text] [Related]
7. Technology evaluation: C242-DM1, ImmunoGen Inc.
Smith S
Curr Opin Mol Ther; 2001 Apr; 3(2):198-203. PubMed ID: 11338934
[TBL] [Abstract][Full Text] [Related]
8. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.
Nanus DM; Milowsky MI; Kostakoglu L; Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Bander NH
J Urol; 2003 Dec; 170(6 Pt 2):S84-8; discussion S88-9. PubMed ID: 14610416
[TBL] [Abstract][Full Text] [Related]
9. Development of a potential high-throughput workflow to characterize sites of bioconjugation by immuno-affinity capture coupled to MALDI-TOF mass spectrometry.
Dai L; Preston R; Bacica M; Kinhikar A; Bolaños B; Murphy RE
Bioconjug Chem; 2013 Jan; 24(1):53-62. PubMed ID: 23186023
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes.
Wakankar AA; Feeney MB; Rivera J; Chen Y; Kim M; Sharma VK; Wang YJ
Bioconjug Chem; 2010 Sep; 21(9):1588-95. PubMed ID: 20698491
[TBL] [Abstract][Full Text] [Related]
11. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer.
Henry MD; Wen S; Silva MD; Chandra S; Milton M; Worland PJ
Cancer Res; 2004 Nov; 64(21):7995-8001. PubMed ID: 15520207
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
Vallabhajosula S; Kuji I; Hamacher KA; Konishi S; Kostakoglu L; Kothari PA; Milowski MI; Nanus DM; Bander NH; Goldsmith SJ
J Nucl Med; 2005 Apr; 46(4):634-41. PubMed ID: 15809486
[TBL] [Abstract][Full Text] [Related]
13. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry.
Wang L; Amphlett G; Blättler WA; Lambert JM; Zhang W
Protein Sci; 2005 Sep; 14(9):2436-46. PubMed ID: 16081651
[TBL] [Abstract][Full Text] [Related]
14. Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate.
Luo Q; Chung HH; Borths C; Janson M; Wen J; Joubert MK; Wypych J
Anal Chem; 2016 Jan; 88(1):695-702. PubMed ID: 26629796
[TBL] [Abstract][Full Text] [Related]
15. Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry.
Sang H; Lu G; Liu Y; Hu Q; Xing W; Cui D; Zhou F; Zhang J; Hao H; Wang G; Ye H
Anal Chim Acta; 2017 Feb; 955():67-78. PubMed ID: 28088282
[TBL] [Abstract][Full Text] [Related]
16. Metal-tag labeling coupled with multiple reaction monitoring-mass spectrometry for absolute quantitation of proteins.
Wang X; Wang X; Qin W; Lin H; Wang J; Wei J; Zhang Y; Qian X
Analyst; 2013 Sep; 138(18):5309-17. PubMed ID: 23869378
[TBL] [Abstract][Full Text] [Related]
17. Determination of pharmacokinetics and tissue distribution of a novel lutetium-labeled PSMA-targeted ligand,
Song CH; Kim K; Kang E; Jeong B; Lee MS; Jung J; Kim TH; Shin S; Shin BS
Sci Rep; 2022 Sep; 12(1):15452. PubMed ID: 36104447
[TBL] [Abstract][Full Text] [Related]
18. Molecules and elements for quantitative bioanalysis: The allure of using electrospray, MALDI, and ICP mass spectrometry side-by-side.
Linscheid MW
Mass Spectrom Rev; 2019 Mar; 38(2):169-186. PubMed ID: 29603315
[TBL] [Abstract][Full Text] [Related]
19. LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1).
Liu Y; Zhou F; Sang H; Ye H; Chen Q; Yao L; Ni P; Wang G; Zhang J
J Pharm Biomed Anal; 2017 Apr; 137():170-177. PubMed ID: 28131055
[TBL] [Abstract][Full Text] [Related]
20. Maytansinoid-BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes.
Fishkin N
Mol Pharm; 2015 Jun; 12(6):1745-51. PubMed ID: 25738231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
